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ABSTRACT
Objectives: To estimate the cost-effectiveness of topical intranasal steroids
for the treatment of otitis media with effusion (OME) in primary care from
the perspective of the UK National Health Service.
Methods: An economic evaluation was conducted based on evidence from
the double-blind, randomized, placebo-controlled GPRF [General Practice
Research Framework] Nasal Steroids for Otitis Media with Effusion
(GNOME) trial. Participants comprised 217 children aged 4–11 years who
had at least one episode of otitis media or related ear problem in the
previous 12 months and had tympanometrically conﬁrmed bilateral OME.
Children were randomly allocated to receive either mometasone furoate
50 mg or placebo spray once daily into each nostril for 3 months. The main
outcome measure was the incremental cost per quality-adjusted life-year
(QALY) gained for topical steroids compared with placebo. The nonpara-
metric bootstrap method was used to present cost-effectiveness acceptabil-
ity curves at alternative willingness to pay thresholds.
Results: Children receiving topical steroids accrued nonsigniﬁcantly
higher costs (incremental cost/child: £11, 95% conﬁdence interval [CI]:
-£199 to £222) and nonsigniﬁcantly fewer QALYs (incremental QALY
gain/child: -0.0166, 95% CI: -0.0652 to 0.0320) than those receiving
placebo. Topical steroids had a 24.19% probability of being cost-effective
at a £20,000 per QALY gained threshold, a 23.82% probability of being
more effective and a 46.25% probability of being less costly. Sensitivity
and subgroup analyses showed incremental costs and beneﬁts to be highly
sensitive to the methods used and the patient group considered, although
differences between groups did not reach statistical signiﬁcance in any
analysis.
Conclusions: Topical steroids are unlikely to be a cost-effective treatment
for OME in general practice.
Keywords: cost-effectiveness, cost-utility analysis, otitis media with effu-
sion, randomized controlled trial.
Introduction
Otitis media with effusion (OME) has been deﬁned as the pres-
ence of ﬂuid in the middle ear without signs or symptoms of
acute ear infection [1]. Epidemiological studies of OME reveal
that it affects 50–80% of children by the age of ﬁve [2,3].
Without effective intervention, severe OME can cause signiﬁcant
hearing loss, which may result in linguistic, developmental,
behavioral, motor, and social impairment [4]. Although many
OME cases resolve spontaneously, referral rates from primary
care remain high, with approximately 1–5 per 1000 children in
the general population undergoing surgery (grommets) each year
[5]. A recent review by the National Institute for Health and
Clinical Excellence (NICE) revealed that grommets are a cost-
effective treatment for children with recurrent otitis media, par-
ticularly for older children [6].
Many nonsurgical treatments, such as decongestants, antihis-
tamines, antibiotics, mucolytics, steroids, and autoinﬂation, are
currently used in the UK National Health Service (NHS) as
short-term treatments for OME in an attempt to avoid unneces-
sary secondary referral and costly surgery [7–10]. However, there
is little evidence that these nonsurgical options are beneﬁcial
[11]. Of the pharmacological nonsurgical treatments currently
provided, further evaluation of topical intranasal corticosteroids
is particularly warranted as evidence of their efﬁcacy is limited to
small clinical trials [12–14] and theoretical beneﬁts, such as
shrinkage of peritubal lymphoid tissue or encroaching adenoidal
tissue that improves tubal function [15,16]. This further evalua-
tion should aim to estimate the cost-effectiveness of topical intra-
nasal corticosteroids in order to provide decision-makers with
evidence on whether the considerable resources currently being
invested in this area represent an efﬁcient use of scarce public
resources.
A companion paper and a Health Technology Assessment
monograph report the methods and results of a recent large
double-blind, randomized, placebo-controlled trial GPRF
[General Practice Research Framework] Nasal Steroids for Otitis
Media with Effusion (GNOME) that compared topical intranasal
corticosteroids with no active treatment in children with bilateral
OME [17,18]. This paper summarizes the methods and results of
an economic evaluation that was based on evidence from the
GNOME trial. To our knowledge, it represents the ﬁrst trial-
based economic evaluation of topical intranasal corticosteroids
for the treatment of OME in primary care.
Methods
Trial Background
The GNOME study (NRR N0575123823) was a placebo-
controlled, double-blind, randomized trial of 217 children aged
4–11 years who had a history of otitis media and tympanometri-
cally conﬁrmed bilateral OME [17,18]. Participating children
were recruited from 76 Medical Research Council (MRC)
General Practice Research Framework (GPRF) practices
throughout the United Kingdom between 2004 and 2007. They
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were randomly allocated to receive either 50 mg mometasone
furoate nasal spray (n = 105) or placebo nasal spray (n = 112)
once daily in each nostril for 3 months. The primary clinical
outcome measure was the proportion of children cured of bilat-
eral OME using tympanometric criteria at one month (i.e., the
proportion of children with at least one ear with an A or C1 type
recording). Secondary clinical outcome measures included: tym-
panometric cure 3 and 9 months postbaseline; OM8-30 scores
[19] 3 and 9 months postbaseline; and diary-based symptoms,
including adenoidal symptoms, snoring, nasal blockage, and rhi-
norrhoea, recorded weekly over the ﬁrst 3 months. Ethical
approval for the trial was granted by the Metropolitan Multi-
centre Research Ethics Committee. Further details of the trial, its
sampling procedures, methodology, outcome measures and
response rates are reported in the companion paper and project
monograph [17,18].
Type of Economic Evaluation, Study Perspective and
Time Horizon
The economic evaluation took the form of a cost–utility analysis
and its primary outcome comprised the incremental cost per
quality-adjusted life-year (QALY) gained through using topical
steroids in place of no active treatment. The QALY, a preference-
based measure that captures gains in both length and health-
related quality of life, is the preferred measure of health outcome
by decision-making bodies such as NICE [20]. Based on recom-
mendations for technology appraisal [20], a UK NHS perspective
was adopted. The analysis took a 9-month time horizon, which
equated to the follow-up period used in the trial.
Measurement of Resource Use
Data were collected about all signiﬁcant health service resource
inputs over the 9-month time horizon. Study data forms provided
a record of: consultations with community health-care providers;
prescribed medications; investigative tests; and hospital inpatient
and outpatient service use, for which the length of stay or con-
sultation, reasons for admission or appointment, any operations
carried out, the name of the hospital provider, its location, and
the ward or clinic attended were recorded. These data were
obtained through two principal means. First, research nurses
employed through the MRC GPRF retrospectively extracted
resource use data from children’s general practice (GP) medical
records. Second, parents completed health service resource utili-
zation questionnaires at 3 and 9 months. Comparisons of the two
sets of resource use data suggested that parents tended to under-
estimate resource use. Subsequently the resource use data
extracted from medical records were used in the base case
analysis.
Valuation of Resource Use
Unit costs were obtained from a variety of secondary sources.
Resource use valuation followed recent guidelines on costing
health services for economic evaluation [19]. Hospital admis-
sions, outpatient consultations, and community health services
were valued using national sources, such as NHS Reference Costs
[21,22] or local provider tariffs, and took account of the cost of
health professionals’ qualiﬁcations where applicable. Drug costs
were obtained from the prescription cost analysis database [23]
and British National Formulary [24]. Costs for individual prepa-
rations were used as well as costs for chemical entities (i.e., drugs
were grouped by chemical entity and the unit costs for these
chemical entities were calculated). The unit costs for the most
commonly used resources are shown in Table 1 and reported in
full in the project monograph [18]. All costs are expressed in UK
pounds sterling and valued at 2006–2007 prices. Unit costs were
combined with resource volumes to obtain a total cost per
Table 1 Resource use, costs (£) and utility scores per child over the nine-month trial period based on complete case analysis
Topical steroids Placebo Difference
Mean SD Mean SD Mean SE* P*
Resource use based on retrospective review of medical records (unit cost per
resource input; N = 100 for topical steroids and 107 for placebo)
No. GP surgery contacts (£31 [22]) 1.67 1.75 1.98 2.03 0.30 0.26 0.252
No. GP home visits (£69 [22]) 0.01 0.10 0.01 0.10 0.00 0.01 0.962
No. GP telephone consultations (£27 [22]) 0.08 0.31 0.10 0.53 0.02 0.06 0.704
No. GP out of hours consultations (£69 [22]) 0.16 0.47 0.08 0.30 0.09 0.06 0.121
No. practice nurse contacts (£29 [22]) 0.38 0.81 0.44 0.86 0.06 0.12 0.611
No. practice nurse telephone consultations (£10 [22]) 0.03 0.17 0.07 0.29 0.04 0.03 0.275
No. district nurse home visits (£23 [22]) 0.00 0.00 0.00 0.00 0.00 0.00 0.000
No. health visitor contacts (£35 [22]) 0.04 0.28 0.07 0.37 0.03 0.05 0.577
No. speech therapist contacts (£40 [22]) 0.03 0.17 0.03 0.17 0.00 0.02 1.00
No. contacts with other community professionals (£29.29 to £362.05 [21,22]) 0.07 0.36 0.03 0.17 0.04 0.04 0.288
No. hospital outpatient referrals (£29.29 to £246.00 [21,22]) 0.53 0.77 0.47 0.66 0.06 0.10 0.563
No. hospital admissions (£458.49 to £2997.20 [21]) 0.18 0.54 0.24 0.47 0.06 0.07 0.230
No. investigative tests (£1.45 to 19.22 [21]) 0.03 0.17 0.09 0.32 0.06 0.04 0.075
Costs (£, based on retrospective review of medical records; N = 100 for topical
steroids and 107 for placebo)
Hospital outpatient costs 54.49 83.38 53.66 80.41 0.83 11.40 0.942
Hospital inpatient costs 280.98 767.06 288.39 611.11 7.40 96.82 0.939
Community health service costs 92.92 136.90 95.44 99.26 2.51 16.72 0.881
Medication costs excluding mometasone 6.04 13.23 11.09 27.32 5.05 2.95 0.089
Topical mometasone 15.66 0.00 — — — — —
Total healthcare costs including mometasone 450.09 842.79 448.57 647.29 1.52 104.97 0.988
Utilities
HUI3 utility
Baseline (N = 63 for steroids, 69 for placebo) 0.777 0.211 0.779 0.241 -0.002 0.039 0.959
3 months (N = 56 for steroids, 54 for placebo) 0.804 0.229 0.877 0.171 -0.073 0.038 0.060
9 months (N = 56 for steroids, 54 for placebo) 0.880 0.208 0.881 0.189 0.000 0.038 0.996
*Standard errors and P-values were calculated in Microsoft Excel 2003 using two-tailed Student’s t-tests assuming unequal variance.
HUI, Health Utilities Index; N, number of children with data; SD, standard deviation; SE, standard error around the mean.
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child covering all categories of hospital and community health
services.
Calculation of Health Utilities and Quality-Adjusted
Life-years (QALYs)
Health utilities were measured using the Health Utilities Index
(HUI) [25] and the EuroQol EQ-5D [26] multiattribute utility
measures. The HUI was introduced into the GNOME study
following a protocol amendment that occurred after 33.2% (72/
217) of the children had been recruited, in order to allow cost–
utility analysis to be conducted. Parents completed the unedited
15-item questionnaire for proxy-assessed usual health status
assessment, which was obtained from the HUI developers and
covers both HUI2 and HUI3 health status classiﬁcation systems.
Standard multiplicative multiattribute utility functions for the
HUI2 and HUI3 (based on a visual analogue scaling technique
and a standard gamble instrument [27,28]) were used to calcu-
late utilities. The EQ-5D questionnaire [26] was also introduced
following the protocol amendment. Both questionnaires were
completed at baseline, 3 and 9 months.
The base case analysis used HUI3 utilities as the HUI3 is now
recommended by the HUI developers because of its broad appli-
cability in both clinical and general population health studies,
improvements in several deﬁnitions, and increased orthogonality
of its attributes for structural independence [29]. Additionally,
the HUI3 contains separate attributes for hearing and speech and
may therefore be more sensitive to small differences in OME
severity than the HUI2 or EQ-5D.
Because preliminary analyses highlighted an imbalance in
baseline utility values between study arms, we adjusted each
child’s utility scores by subtracting their baselines utility score
from their Utility scores at 3 and 9 months postrandomization,
so that each on-treatment measurement indicates the increase (or
decrease) in utility from baseline [30]. The number of QALYs
gained/lost relative to baseline was calculated as the area under
the baseline-adjusted utility curve, assuming linear interpolation
between the three utility measurements.
Methods for Dealing with Missing Data
Multiple imputation [31,32] was used to impute missing data
and avoid biases associated with complete case analysis [31].
Missing data was a particular issue for utility scores. However,
although no utility data were available for children recruited
early in the trial, utility scores were found to correlate well [33]
with the scores on the disease-speciﬁc OM8-30 questionnaire
[19] that were available for most children. Consequently, mul-
tiple imputation took account of the predicted HUI3 utility
scores that were estimated using a mapping algorithm developed
using the GNOME trial data that predicts children’s HUI3 utility
scores based on OM8-30 facet scores [33].
The “ice” command within Stata (Version 10.0; Stata Corp,
College Station, TX) [34] was used to impute missing data for the
following variables: log-transformed total cost based on data from
medical records and that from parental questionnaires; log-
transformed disutilities at baseline, 3, and 9 months using the
HUI3, HUI2, and EQ-5D measures; predicted HUI3 utilities at
baseline, 3, and 9 months estimated using the OM8-30 mapping
equation [33]; and whether OME was cured at either 1 or 3
months. Age, sex, and treatment allocation were included as
additional explanatory variables in the imputation models. The
“match” option within “ice” was used for disutilities and costs as
this algorithm is less dependent on assumptions of normality than
default options. Five imputed datasets were generated. Imputed
values were transformed back to a natural scale where required.
Cost-Effectiveness Analytical Methods
Independent-sample t-tests were used to test for differences in
resource use, costs, utility scores, and QALYs between treatment
groups. All statistical tests were two-tailed.
The ﬁve imputed datasets generated through multiple impu-
tation were bootstrapped [35] separately in Microsoft Excel
2003 (Microsoft Corporation, Redmond, WA) and the results
were combined using equations described by Briggs et al. [31] to
calculate standard errors around mean costs and effects that
incorporate uncertainty around imputed values as well as sam-
pling variation. Standard errors were used to calculate 95%
conﬁdence intervals (CIs) around total and incremental costs and
QALYs based on Student’s t-distribution.
Cost-effectiveness acceptability curves [36], showing the
probability that topical steroids are cost-effective relative to no
active treatment at a range of ceiling ratios were generated based
on the proportion of bootstrap replicates (across all ﬁve imputed
datasets) with positive incremental net beneﬁts [37]. Incremental
net beneﬁt was deﬁned as the incremental QALY gain multiplied
by the ceiling ratio minus the incremental cost [37], where the
ceiling ratio (or threshold) represents the maximum society is
willing or able to pay for each additional QALY. Unless other-
wise stated, all statements about cost-effectiveness are based on a
£20,000 per QALY gained threshold [20]. The probability that
topical steroids are less costly or more effective than no treatment
was based on the proportion of bootstrap replicates that had
negative incremental costs or positive incremental QALYs,
respectively. In order to assess the value of collecting further
information and quantifying the consequences of the uncertainty
around the decision, we also estimated the expected value of
perfect information (EVPI), which reﬂects the theoretical
maximum amount that we should consider spending on further
research that would eliminate all decision uncertainty [38]. The
EVPI per child was estimated by subtracting the total net beneﬁt
for the option we would choose based on current information
from the maximum net beneﬁt we would obtain with perfect
information (the average of the maximum net beneﬁt for each
bootstrap replicate). No discounting was applied to costs and
health effects as the time horizon for the economic evaluation
was less than 1 year.
Several sensitivity analyses [36] were undertaken to assess the
impact of areas of uncertainty surrounding components of the
economic evaluation. These included: 1) basing costs on
responses to parental questionnaires; 2) basing the economic
evaluation on a complete case analysis; 3) basing utilities on the
HUI2 measure; 4) basing utilities on the EQ-5D measure; and 5)
making no adjustment to baseline utilities. Results were also
calculated for subgroups of children stratiﬁed by key character-
istics: 1) age (<6.5 years, 6.5 years); 2) gender (boys, girls); 3)
atopy (yes, no); 4) baseline clinical severity score (upper quartile
[severe disease], children with less severe disease); 5) month of
recruitment (January–March, April–December); and 6) period of
trial recruitment (prior to protocol amendment described above,
following protocol amendment). All subgroup analyses were post
hoc.
Results
The main clinical results of the trial are presented in the com-
panion paper and project monograph [17,18]. In brief, 40.6%
(39/96) of the topical steroid group and 44.9% (44/98) of the
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placebo group achieved tympanometric cure (C1 or A type) in
one or both ears at 1 month (adjusted odds ratio: 0.934, 95% CI:
0.498–1.751, P = 0.831). There were no signiﬁcant differences
between the two groups in any secondary outcomes at 1, 3, or 9
months.
Health Service Resource Use and Costs
Resource use data from medical records were available for 95%
(207/217) of the children (Table 1). There was no signiﬁcant
difference between the groups for any category of health service
resource use or costs (P > 0.05). Overall, this population of chil-
dren with OME managed in primary care attended an average of
1.83 (standard deviation [SD]: 1.90) GP consultations in the
9-month study period. Based on cases with complete cost data,
the total cost of managing children randomized to topical ste-
roids was £450.09 per child over the 9-month study period,
compared with £448.57 per child for the placebo group
(P = 0.60). Although only 19% (39/207) of children were admit-
ted to hospital, inpatient care accounted for 63% of total costs,
with each hospital admission costing an average of £284.80 (SD:
£689.16).
Although the complete case analysis (Table 1) suggested that
use of topical steroids increased total costs by just £1.52 per child
(P = 0.99), the incremental cost per child rose to £11.23
(P = 0.91) when missing cost data were estimated using multiple
imputation and all children were included in the analysis
(Table 2).
Health Utilities
Because of the late introduction of multiattribute utility measures
and noncompletion of questionnaires, 94% (202/216) of HUI3
utility measurements for children recruited before the protocol
amendment and 22% (97/435) of those for children recruited
after the protocol amendment were missing. Utility scores were
similar across the two study groups and there was no signiﬁcant
difference between groups in HUI3 utility scores at any time
point. However, both groups showed an increase in utility score
from an overall mean HUI3 utility score of 0.778 (SD = 0.226,
N = 132) at baseline to 0.840 (SD = 0.205, N = 110) at 3 months
and 0.880 (SD = 0.198, N = 110) at 9 months (complete case
analysis). Children achieving tympanometric cure at 3 months
had a mean HUI3 utility score of 0.854 (SD = 0.193, N = 63) at
this time point, compared with 0.828 (SD = 0.202, N = 42) for
children not achieving tympanometric cure (P = 0.516; complete
case analysis).
Both mapping techniques and multiple imputation suggested
that those children with missing utility data had slightly lower
utility scores than those with complete data; imputing missing
data therefore reduced mean utilities slightly (Tables 1 and 2).
However, there was no signiﬁcant difference in health utilities
between the study groups regardless of the methodology used.
In the base-case analysis, which includes both baseline adjust-
ment of utility scores (subtracting baseline utility from
on-treatment utility scores) and multiple imputation, children
randomized to topical steroids accrued 0.017 fewer QALYs than
those randomized to placebo (P = 0.48; Table 2).
Cost-Utility Analysis
The base-case analysis suggested that, on average, topical ste-
roids were dominated by no active treatment, costing an addi-
tional £11.23 (bootstrap 95% CI: -£199.14 to £221.60), with a
net loss of 0.017 (-0.032–0.065) QALYs per child treated
(Table 3). However, there is substantial uncertainty around this
ﬁnding. Based on the distribution of bootstrap replicates, there is
a 46% probability that treating children with topical steroids
would accrue lower costs than no active treatment, as well as a
24% probability that active treatment would generate more
QALYs. The probability of topical steroids being cost-effective
Table 2 Costs (£), utilities and quality-adjusted life-years (QALYs) per child over the nine-month trial period, including values imputed using multiple
imputation
Topical steroids (N = 105) Placebo (N = 112) Difference
Mean SE† Mean SE† Mean SE‡ P§
Total cost (£)
Medical records 453.54 82.14 442.31 61.84 11.23 101.85 0.912
Parents’ questionnaires 458.31 97.80 273.60 60.84 184.71 121.33 0.129
HUI3 utilities
Baseline 0.758 0.044 0.766 0.758 -0.008 0.034 0.815
3 months 0.776 0.061 0.836 0.776 -0.060 0.034 0.073
9 months 0.876 0.027 0.871 0.876 0.004 0.037 0.908
HUI2 utilities
Baseline 0.849 0.027 0.855 0.849 -0.006 0.027 0.831
3 months 0.890 0.031 0.901 0.890 -0.011 0.022 0.627
9 months 0.919 0.017 0.897 0.919 0.022 0.022 0.323
EQ-5D utilities
Baseline 0.884 0.039 0.913 0.884 -0.029 0.036 0.424
3 months 0.937 0.019 0.917 0.937 0.021 0.024 0.402
9 months 0.928 0.024 0.923 0.928 0.004 0.034 0.904
Unadjusted QALYs
HUI3 0.605 0.031 0.627 0.605 -0.023 0.018 0.218
HUI2 0.670 0.015 0.669 0.670 0.001 0.012 0.943
EQ-5D 0.694 0.012 0.689 0.694 0.005 0.015 0.735
Baseline-adjusted QALYs
HUI3 0.036 0.018 0.053 0.036 -0.017 0.024 0.480
HUI2 0.033 0.012 0.028 0.033 0.005 0.016 0.737
EQ-5D 0.031 0.022 0.004 0.031 0.027 0.022 0.220
†Standard errors were calculated across all ﬁve imputed datasets using methods described previously [31].
‡SE2difference = SE2Treatment + SE2placebo.
§Based on a two-tailed t-test conducted in Microsoft Excel 2003 whereby t equaled mean divided by standard error and p was calculated based on the t-distribution in Excel.
HUI, Health Utilities Index; QALY, quality-adjusted life year; SE, standard error.
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compared with no active treatment was found to be 24.2% at a
£20,000 per QALY threshold, and 23.9% at a £30,000 per
QALY threshold (Fig. 1).
EVPI was found to equal £65.73 per child or £9.1 million for
the 160,000 children in the United KIngdom who would be
potentially eligible for treatment over the next 10 years based on
the recruitment rate observed at the 76 GP practices participating
in GNOME (discounted at 3.5% per annum). EVPI reﬂects the
theoretical maximum that it would be cost-effective to spend on
further research that would eliminate all uncertainty around the
decision. In this case, the EVPI is higher than the cost of many
trials, which suggests that it may be cost-effective to collect
further evidence on the efﬁcacy and cost-effectiveness of steroids
for OME. However, optimal decisions regarding future research
would need to also take account of the costs of research and the
extent to which any given trial would reduce the chance and cost
of making the wrong decision.
Sensitivity Analyses
Sensitivity analyses explored the impact of varying the methods
and values used in the economic evaluation (Table 3, Fig. 1).
Basing health service resource use estimates on parental question-
naires rather than medical records reduced mean costs in the
placebo group by 44%, increased the incremental cost of topical
steroids to £185 (bootstrap 95% CI: -£69 to £438) per child and
decreased the probability that treatment is cost-effective at a
£20,000 per QALY threshold to 14%.
Conducting a complete case analysis on 104 out of the 217
children with complete cost and utility data substantially
increased incremental costs and beneﬁts, although topical ste-
roids remained dominated by no active treatment with a 25%
chance of being cost-effective.
However, based on HUI2 utilities, the average child receiving
topical steroids accrued 0.005 (-0.028–0.038) more QALYs than
those receiving no active treatment, giving an incremental cost
per QALY gained of £2161. Although this point estimate would
be considered cost-effective, if society were willing to pay
£20,000 for an additional QALY, uncertainty around costs and
beneﬁts meant that the probability of treatment being cost-
effective was 63%. Similarly, when the EQ-5D instrument was
used, the incremental cost per QALY gained was estimated at
£418 and steroids were found to have an 89% probability of
being cost-effective at a £20,000 per QALY threshold. Finally,
not adjusting for baseline utility slightly increased the QALY loss
from treatment and reduced the probability of treatment being
cost-effective to 12%.
Subgroup Analyses
Total and incremental costs and QALYs attributable to topical
steroids differed substantially between patient subgroups
(Table 4). Total costs were lower in the treatment group than the
placebo group for six of the 12 subgroups investigated, with the
largest savings occurring in older children and those with less
severe disease. By contrast, the treatment group accrued fewer
QALYs than the placebo group in all 12 subgroups. Overall,
there were no subgroups in which the probability of cost-
effectiveness exceeded 45% at the £20,000 per QALY threshold.
Discussion
The study reported in this paper represents a comprehensive
economic evaluation of topical intranasal steroids for the treat-
ment of 4–11-year-old children with OME in primary care. It
represents, to our knowledge, the ﬁrst economic evaluation ofTa
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topical steroids for children with OME. The economic evaluation
was conducted according to nationally agreed design and report-
ing guidelines [20,39]. It was based on the largest double-blind,
randomized, placebo-controlled trial of topical steroids in chil-
dren with OME in any health setting, and larger than the only
previous randomized control trial from primary care which
evaluated antibiotic use for this condition [40]. The GNOME
trial enabled collection of a broad range of resource use, clinical
effectiveness, and health utility data that may inform future
economic evaluations of other OME interventions. Moreover,
the costing analysis was rigorous and included all signiﬁcant
resource items calculated from a health service perspective.
The economic evaluation found that topical steroids are
unlikely to be a cost-effective treatment for OME in this primary
care population and (based on current evidence) there are no
grounds for adopting mometasone as a treatment for OME in
this patient group. The cost–utility analysis showed active treat-
ment to be dominated by no active treatment, costing an addi-
tional £11 and producing 0.017 fewer QALYs per child treated
(on average), although treatment groups did not differ signiﬁ-
cantly in either costs or beneﬁts. Moreover, this conclusion
remained relatively robust in sensitivity analyses that accounted
for the uncertainty surrounding components of the economic
evaluation. Furthermore, subgroup analyses demonstrated that
active treatment may cause harm in some subgroups: there was a
72% probability that topical steroids would reduce the number
of QALYs accrued in older children (6.5 years) and an 83%
probability in children with severe disease.
A number of caveats should be noted when interpreting the
study results. First, the method of recruitment into the GNOME
study, which included formal audits by research nurses with
invitations for tympanometric screening [17,18], is likely to have
more accurately identiﬁed a population for treatment than is
usually the case in primary care. This may limit the generaliz-
ability of the study ﬁndings to actual practice where treatments
may be given with less certainty of accurate diagnosis. Neverthe-
less, additional analyses showed that the study population had
presented to their GP with an otitis media or ear problem
episode, on average, on two occasions in the previous year, which
is typical of primary care practice [11]. In addition, comparisons
of the characteristics of the GNOME study population with
those from other studies, including the Trial of Alternative Regi-
mens in Glue Ear Treatment (TARGET) trial and Eurotitis
samples, revealed that the GNOME study population did not
differ signiﬁcantly in terms of baseline OM8-30 scores [41].
Second, the economic evaluation used a 9-month time
horizon based on the study follow-up period. Although topical
steroids were only given for 3 months, NHS resource use and
health consequences may have extended beyond the end of the
treatment because of incomplete resolution of OME and relapse.
The 9-month time horizon used in the economic evaluation is
likely to have captured all relevant health service resource use
and health consequences; the absence of signiﬁcant differences in
costs or health outcomes over the 9-month period suggests that
long-term extrapolation would not have affected the ﬁndings.
Third, by adopting the recommended NHS perspective [20],
the economic evaluation excluded wider costs, such as costs
borne by other sectors of the economy, parents, informal carers,
and employers. This was primarily the result of preliminary
research we had conducted, which suggested that accurate mea-
surement of non-NHS costs would have required far more
research intensive involvement with parents during the follow-up
period. Our preliminary research suggested that this may have
affected response rates to the parental questionnaires, thereby
diluting the overall credibility of the study ﬁndings. Given the
nonsigniﬁcant study ﬁndings for the primary and secondary clini-
cal outcomes, it is unlikely that including non-NHS costs would
have affected the study conclusions. Nevertheless, OME as a
condition may lead to costs to education services, personal and
social services, parents, informal carers, and employers that
future economic evaluations in this area should consider, at least
within sensitivity analyses.
Fourth, the base-case cost–utility estimates in the study were
based on HUI3 utility scores derived from questionnaires com-
pleted by parents. Recent methodological guidance in England
and Wales recommends that health-related quality of life should
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Figure 1 Cost-effectiveness acceptability curves for the base-case analysis and sensitivity analyses. QALY, quality-adjusted life-year.
548 Petrou et al.
Ta
bl
e
4
In
cr
em
en
ta
lc
os
t-
ef
fe
ct
iv
en
es
s
ra
tio
s
fo
r
su
bg
ro
up
an
al
ys
es
Su
bg
ro
up
*
M
ea
n
co
st
s
(9
5%
C
I)
M
ea
n
Q
A
LY
s
ga
in
ed
re
la
tiv
e
to
ba
se
lin
e
ut
ili
ty
(9
5%
C
I)
N
o.
ch
ild
re
n†
C
os
t/
Q
A
LY
(£
)
Pr
ob
ab
ili
ty
ac
tiv
e
tr
ea
tm
en
t
is
A
ct
iv
e
(£
)
Pl
ac
eb
o
(£
)
D
iff
er
en
ce
(£
)
A
ct
iv
e
Pl
ac
eb
o
D
iff
er
en
ce
A
ct
iv
e
Pl
ac
eb
o
C
os
t-
ef
fe
ct
iv
e
(%
)‡
M
or
e
ef
fe
ct
iv
e
(%
)
Le
ss
co
st
ly
(%
)
C
hi
ld
re
n

6.
5
ye
ar
s
26
0
(1
14
,4
05
)
41
2
(2
22
,6
01
)
-1
52
(-
38
2,
79
)
0.
04
3
(-
0.
00
4,
0.
09
0)
0.
06
6
(-
0.
00
2,
0.
13
4)
-0
.0
23
(-
0.
10
2,
0.
05
6)
37
38
6,
61
1
(S
W
)
35
.0
6
28
.2
2
90
.3
8
C
hi
ld
re
n
<
6.
5
ye
ar
s
55
9
(3
13
,8
05
)
45
8
(3
01
,6
15
)
10
1
(-
18
5,
38
7)
0.
03
2
(-
0.
01
8,
0.
08
2)
0.
04
6
(0
.0
10
,0
.0
82
)
-0
.0
14
(-
0.
06
7,
0.
04
0)
68
74
D
om
in
at
ed
(-
7,
42
2)
25
.5
0
30
.0
2
24
.9
6
Bo
ys
52
7
(2
67
,7
86
)
46
5
(2
99
,6
30
)
62
(-
24
1,
36
5)
0.
04
5
(-
0.
00
8,
0.
09
8)
0.
06
2
(0
.0
01
,0
.1
23
)
-0
.0
17
(-
0.
08
9,
0.
05
6)
52
63
D
om
in
at
ed
(-
3,
68
6)
27
.6
2
30
.1
0
34
.5
2
G
ir
ls
38
2
(1
69
,5
95
)
41
4
(2
32
,5
95
)
-3
2
(-
31
1,
24
7)
0.
02
8
(-
0.
04
5,
0.
10
0)
0.
04
1
(-
0.
02
1,
0.
10
3)
-0
.0
14
(-
0.
08
1,
0.
05
3)
53
49
2,
32
2
(S
W
)
35
.4
6
32
.2
6
60
.6
4
A
to
py
44
9
(1
63
,7
35
)
39
8
(2
29
,5
67
)
51
(-
25
9,
36
1)
0.
03
8
(-
0.
01
9,
0.
09
5)
0.
05
3
(-
0.
00
3,
0.
11
0)
-0
.0
15
(-
0.
10
0,
0.
07
0)
35
33
D
om
in
at
ed
(-
3,
34
1)
34
.0
2
35
.1
8
39
.3
8
N
o
at
op
y
45
6
(2
48
,6
64
)
46
1
(3
05
,6
16
)
-5
(-
26
5,
25
5)
0.
03
5
(-
0.
00
9,
0.
07
9)
0.
05
3
(0
.0
12
,0
.0
93
)
-0
.0
17
(-
0.
06
9,
0.
03
4)
70
79
28
6
(S
W
)
24
.8
2
24
.3
2
51
.2
0
Se
ve
re
(c
lin
ic
al
se
ve
ri
ty
sc
or
e
>
0.
62
)
58
6
(2
48
,9
24
)
44
2
(2
20
,6
64
)
14
5
(-
26
0,
54
9)
0.
02
0
(-
0.
07
7,
0.
11
7)
0.
07
4
(0
.0
07
,0
.1
41
)
-0
.0
54
(-
0.
18
2,
0.
07
4)
23
23
D
om
in
at
ed
(-
2,
69
0)
14
.4
6
16
.7
6
24
.6
2
N
on
se
ve
re
(c
lin
ic
al
se
ve
ri
ty
sc
or
e

0.
62
)
36
7
(1
67
,5
66
)
46
0
(3
00
,6
19
)
-9
3
(-
34
5,
15
9)
0.
03
7
(-
0.
00
2,
0.
07
7)
0.
05
1
(0
.0
05
,0
.0
96
)
-0
.0
13
(-
0.
06
5,
0.
03
8)
65
75
7,
07
4
(S
W
)
37
.6
2
30
.3
4
76
.4
6
Se
as
on
1:
en
ro
lle
d
Ja
nu
ar
y–
M
ar
ch
45
1
(2
07
,6
94
)
32
6
(2
03
,4
48
)
12
5
(-
15
0,
40
0)
0.
04
3
(0
.0
03
,0
.0
84
)
0.
05
3
(0
.0
05
,0
.1
02
)
-0
.0
10
(-
0.
07
3,
0.
05
3)
42
44
D
om
in
at
ed
(-
12
,4
51
)
31
.0
4
37
.9
0
17
.1
6
Se
as
on
2:
en
ro
lle
d
A
pr
il–
D
ec
em
be
r
45
6
(2
32
,6
79
)
51
8
(3
34
,7
02
)
-6
2
(-
35
4,
22
9)
0.
03
1
(-
0.
02
7,
0.
09
0)
0.
05
2
(0
.0
08
,0
.0
96
)
-0
.0
21
(-
0.
08
9,
0.
04
7)
63
68
2,
96
3
(S
W
)
30
.3
0
25
.8
6
67
.2
6
Ea
rl
y
tr
ia
lp
er
io
d
w
ith
ac
tiv
e
m
on
ito
ri
ng
41
7
(1
33
,7
01
)
56
6
(3
31
,8
02
)
-1
49
(-
52
3,
22
4)
0.
02
1
(-
0.
08
4,
0.
12
6)
0.
03
3
(-
0.
03
2,
0.
09
8)
-0
.0
12
(-
0.
11
4,
0.
08
9)
35
37
12
,2
49
(S
W
)
44
.4
8
38
.0
0
78
.7
6
La
te
r
tr
ia
lp
er
io
d
w
ith
ou
t
ac
tiv
e
m
on
ito
ri
ng
47
2
(2
66
,6
77
)
38
1
(2
49
,5
13
)
91
(-
15
4,
33
5)
0.
04
4
(0
.0
14
,0
.0
73
)
0.
06
2
(0
.0
24
,0
.1
00
)
-0
.0
19
(-
0.
06
6,
0.
02
8)
70
75
D
om
in
at
ed
(-
4,
83
8)
17
.3
6
21
.1
0
24
.2
0
*A
ll
an
al
ys
es
sh
ow
n
in
th
is
ta
bl
e
w
er
e
ba
se
d
on
10
00
bo
ot
st
ra
p
re
pl
ic
at
es
fo
r
ea
ch
of
th
e
ﬁv
e
im
pu
te
d
da
ta
se
ts
.
† S
ub
gr
ou
p
an
al
ys
es
om
it
an
y
ch
ild
re
n
w
ith
m
is
si
ng
da
ta
on
th
e
pa
ra
m
et
er
us
ed
to
de
ﬁn
e
th
e
su
bg
ro
up
bu
t
in
cl
ud
e
th
os
e
ch
ild
re
n
w
ith
im
pu
te
d
va
lu
es
fo
r
co
st
s
or
qu
al
ity
of
lif
e.
‡ T
re
at
m
en
t
w
as
co
ns
id
er
ed
to
be
“c
os
t-
ef
fe
ct
iv
e”
if
it
ha
d
po
si
tiv
e
ne
t
be
ne
ﬁt
at
a
£2
0,
00
0/
Q
A
LY
ce
ili
ng
ra
tio
.
C
I,
[b
oo
ts
tr
ap
]
co
nﬁ
de
nc
e
in
te
rv
al
;H
U
I,
H
ea
lth
U
til
iti
es
In
de
x;
Q
A
LY
,q
ua
lit
y-
ad
ju
st
ed
lif
e-
ye
ar
;S
W
,s
ou
th
-w
es
t
qu
ad
ra
nt
of
th
e
co
st
-e
ffe
ct
iv
en
es
s
pl
an
e
(IC
ER
s
in
th
e
SW
qu
ad
ra
nt
in
di
ca
te
th
at
ac
tiv
e
tr
ea
tm
en
t
is
le
ss
co
st
ly
an
d
le
ss
ef
fe
ct
iv
e
th
an
pl
ac
eb
o
an
d
IC
ER
s
lo
w
er
th
an
th
e
ce
ili
ng
ra
tio
sh
ou
ld
be
co
ns
id
er
ed
no
t
co
st
-e
ffe
ct
iv
e,
be
ca
us
e
th
ey
in
di
ca
te
th
at
th
e
sa
vi
ng
s
ar
e
no
t
su
fﬁ
ci
en
tly
la
rg
e
to
w
ar
ra
nt
th
e
nu
m
be
r
of
Q
A
LY
s
th
at
w
ou
ld
be
lo
st
).
Economic Evaluation of Topical Steroids for OME 549
normally be measured directly by patients themselves using the
EQ-5D multiattribute utility measure [20]. At the outset of the
study, it was felt that younger children in the GNOME sample
would lack the comprehension level required for the available
multiattribute utility measures and that parental measurement
would be required [42,43]. Moreover, the available psychometric
evidence suggested that the HUI3 has greater construct and
empirical validity than the EQ-5D in childhood [42–44]. Further-
more, post hoc analyses on the GNOME data suggested that the
HUI is more sensitive to differences in tympanometric cure in our
study population than the EQ-5D (details available upon
request). Consequently, the conclusions for the economic evalu-
ation should, in our opinion, primarily be based on the HUI3-
derived incremental cost-utility estimates.
Finally, and related to the fourth caveat, there is a more
general concern about the psychometric properties of all the
available multiattribute utility measures when applied to children
as young as 4 years of age, of which there were some in our study
population. Researchers have previously noted that there are
likely to be dimensions of health status relevant to young chil-
dren not reﬂected by the available multiattribute utility measures
[42]. Until the recommended multiattribute utility measures
reﬂect health experiences across all age groups, health econo-
mists are likely to continue to rely on the available, but con-
strained, measures for the purposes of economic evaluation.
In conclusion, our study suggests that topical intranasal cor-
ticosteroids are unlikely to be a cost-effective treatment for OME
in general practice. However, value of information analysis sug-
gests that future research in this area may be cost-effective. Data
on the costs and health-related quality of life of children with
OME that were collected in our study may be used to inform
future economic evaluations and other empirical research studies
in this area.
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